Abstract
An early lead from the AMD070 program was optimized and a structure-activity relationship was developed for a novel series of heterocyclic containing compounds. Potent CXCR4 antagonists were identified based on anti-HIV-1 activity and Ca(2+) flux inhibition that displayed good pharmacokinetics in rat and dog.
Copyright © 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Aminoquinolines
-
Animals
-
Anti-HIV Agents / chemical synthesis*
-
Anti-HIV Agents / chemistry
-
Anti-HIV Agents / pharmacokinetics
-
Benzimidazoles
-
Butylamines
-
Calcium Signaling
-
Dogs
-
HIV-1 / drug effects*
-
HIV-1 / physiology
-
Heterocyclic Compounds, 1-Ring / chemistry
-
Humans
-
Rats
-
Receptors, CXCR4 / antagonists & inhibitors*
-
Receptors, CXCR4 / metabolism
-
Structure-Activity Relationship
-
Virus Replication / drug effects*
Substances
-
Aminoquinolines
-
Anti-HIV Agents
-
Benzimidazoles
-
Butylamines
-
Heterocyclic Compounds, 1-Ring
-
Receptors, CXCR4
-
mavorixafor